Leelamine (Synonyms: Dehydroabietylamine, NSC 2955) |
| Catalog No.GC44048 |
릴라민은 칸나비노이드 수용체 CB1과 CB2의 약한 작용제입니다. 릴라민은 또한 피루브산 탈수소효소 키나제(PDK)를 억제합니다. 릴라민은 항종양 활성을 나타냅니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1446-61-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Leelamine is a diterpene molecule whose name derives from the Sanskrit word leela which means "play". It has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, exhibiting 20% displacement of [3H]-CP55940 at a concentration of 10 µM. Leelamine inhibits pyruvate dehydrogenase kinase (PDK) with an IC50 value of 9.5 µM. Derivatives of leelamine exhibit anti-inflammatory activity and show moderate inhibition of phospholipase A2 activity from a variety of sources.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *